

Jeremy A. Adler, MS, PA-C

(Co-Owner, Chief Operating Officer)

Education & Training:

Medical Training: State University of New York, Stony Brook
Bachelor of Science, Physician Assistant
Summa Cum Laude

University of Nebraska Medical Center
Masters, Physician Assistant
Specialty: Pain Management/Physical Medicine
Summa Cum Laude

Undergraduate: University of California, San Diego
Bachelor of Science, General Biology

Board Certifications: National Commission of Certification of PAs
Credentialed Pain Practitioner – American Academy of Pain Management

Specialized Training: Medtronic Intrathecal Drug Delivery Course for Healthcare Providers
Medtronic Spinal Cord Stimulator Course
Advanced Neuromodulation Systems Spinal Cord Stimulation Course
Boston Scientific Spinal Cord Stimulation Cadaver Course
Controlled Substance Education Course, CAPA
Advanced/Basic Cardiac Life Support Certified

Additional Qualifications: TIRF (Transmucosal Immediate Release Fentanyl) Certified
DEA Registration Schedule II-V
Course Developer/Moderator – Controlled Substance Education Course, CAPA
Medical Expert Reviewer (Malpractice Reviewer for Pain/PA Issues)

Healthcare Leadership: President-Elect, California Academy of PAs
Founder & Past President, San Diego Society of PAs
Board of Directors, American Academy of Pain Medicine Foundation
Founding President, National Society of Pain Care Providers (PainCAP)
Clinical Practice Guidelines Committee, American Pain Society/AAPM
Primary Care Special Interest Group Member, American Academy of Pain Medicine
CURES 2.0 Upgrade, California Department of Justice
Professional Practice Committee Member, CAPA
San Diego County Medical Corp, California Health Alert Network

Select Publications:

Adler, J. Prescription Drug Abuse – Is Rescheduling Hydrocodone the Answer? May/June 2013. *CAPA News: Official Publication of the California Academy of Physician Assistants*, p. 8-9,20.

Adler, J. Medical and Pharmacy Boards' Promote Controlled Substance Education ... CAPA Delivers! March/April 2013. *CAPA News: Official Publication of the California Academy of Physician Assistants*, p. 8-9.

Adler, J. Can California Physician Assistants write for Suboxone® and Subutex® (or generic)? January/February 2013. *CAPA News: Official Publication of the California Academy of Physician Assistants*, p. 6-7.

Adler, J. Bill would bring measure of relief to pain patients. August 22, 2012, *San Diego Union Tribune*. <http://www.utsandiego.com/news/2012/aug/22/bill-would-bring-measure-of-relief-to-pain/?print&page=all>

Adler J, Fitzgerald M (eds). Addressing Acute Pain Management in Primary Care. *The Clinical Advisor*. 2012;Volume Number;(August supplement):1-16

Adler, J. I'm Registered with CURES, Now What?. July/August 2012. *CAPA News: Official Publication of the California Academy of Physician Assistants*, p. 6-7.

Adler, J. Get Registered with the CURES Program. March/April 2012. *CAPA News: Official Publication of the California Academy of Physician Assistants*, p. 10-11.

Pain Medicine News. The APS/AAPM Opioid Treatment Guidelines Revisited: Interview with **Jeremy A. Adler, MS, PA-C**, Jane C. Ballantyne, MD, Roger Chou, MD, Gilbert Fanciullo, MD, Perry G. Fine, MD, David Fishbain, MD and Steven Passick, PhD. December 2011. *Pain Medicine News Special Edition*. 6th Annual Compendium of Clinical Reviews in Pain Management. (9)12; pp 6-9.

Lavelle, J. Need a Job? Physician Assistant is in Healthy Demand: A Weekly Conversation. Interview with **Jeremy Adler**. Sept 26, 2011, *San Diego Union Tribune*. Business Section C1-2.. <http://www.signonsandiego.com/news/2011/sep/26/medic-is-in-healthy-demand/>

Adler, J. Once-Daily Cyclobenzaprine Extended-Release for Acute Muscle Spasm: Expanding Pain Management Options for Clinicians and Patients. May 2011, *Clinician Reviews*. 21(5 Suppl.), p 1-6. <http://www.clinicianreviews.com/PDF/021050000.pdf>

Argoff C, McCarberg B, **Adler J**, Brown L, Henderson K, Patel N, Polomano R, Silverman S, Stanos S, Ajluni P, Cowan P, Inturrisi C, Kiley D, Marcus N, Pagels P, Ray A, Rowe W, Windle K Expert Panel Recommends Collaboration in the Pain Management Community to Improve Diagnosis and Treatment May 2009, *Monthly Prescribing Reference*. CME Monograph; pp 1-11. <http://www.mycme.com/Underdiagnosis--Undertreatment-of-Pain/activity/87/>

Chou R, Fanciullo G, Fine, P, **Adler J**, Ballantyne J, Davies P, Donovan M, Fishbain D, Foley K, Fudin J, Gilson A, Kelter A, Mauskop A, O'Connor P, Passik S, Pasternak G, Portenoy R, Rich B, Roberts R, Saper J, Todd K, Miaskowski C Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain Feb 2009, *J Pain*. (10)2; pp 113-30.e22. [http://www.jpain.org/article/S1526-5900\(08\)00831-6/abstract](http://www.jpain.org/article/S1526-5900(08)00831-6/abstract)

McCarberg, BH and **Adler JA** Updates on Managing Acute and Chronic Pain in Primary Care Practice. Optimizing Pain Reduction, Minimizing Adverse Events. *JAAPA* October 2008, Suppl http://www.jaapa.com/issues/j20081001/pdfs/08-70_jaapa_pain_final.pdf

Pain Management for Primary Care Clinicians; Arthur G. Lipman, Amer Soc Health-System Pharmacists; (April 1, 2004) (Expert Reviewer)

Research Projects:

- SENSE™ (Subcutaneous and Epidural Neuromodulation System Evaluation) Study (St. Jude)
The SENSE™ study is a prospective, multi-center, parallel design randomized, double-blinded study to demonstrate safety and efficacy of Peripheral Nerve field Stimulation (PNFS) and Spinal Cord Stimulation in combination with Peripheral Nerve field Stimulation (SCS-PNFS) using a St. Jude Medical Neuromodulation System.
(<http://clinicaltrials.gov/ct2/show/NCT01990287?term=sense&rank=1>)
- Superion® ISISS Trial - Protocol #08-VISS-01 (Vertiflex®)

The Superior® InterSpinous Spacer (ISS) study is a prospective, multi-center, randomized controlled clinical trial comparing the Superior® ISS to the X-STOP® IPD® device in the treatment of subjects aged 45 or older suffering from moderate symptoms of neurogenic intermittent claudication secondary to a confirmed diagnosis of lumbar spinal stenosis (LSS) at one or two contiguous levels from L1 to L5.

<http://clinicaltrials.gov/ct2/show/NCT00692276?term=08-VISS-01&rank=1>

- ConVERT - Conversion to Embeda® with Rescue Trial Study (King Pharmaceuticals)
Study designed to assess the success of converting opioid-experienced, moderate to severe chronic pain patients to a stable dose of EMBEDA® using a standardized conversion guide.
<http://clinicaltrials.gov/ct2/show/NCT01179191?term=convert+embeda&rank=1>
- Pharmacogenetic Saliva Study Assay Analysis (Protocol ML-001-2012)
(Millennium Laboratories)
- Medtronic Neuromodulation RestoreSensor™ IDE Study (Protocol #1651)
The RestoreSensor™ Study is a prospective, multi-center, open-label, randomized crossover study to gather clinical information in subjects with and without the use of AdaptiveStim™ feature of the RestoreSensor™ Model 37714 implantable neurostimulator (INS)
<http://clinicaltrials.gov/ct2/show/NCT01106404?term=restoresensor&rank=2>
- Ziconotide Effectiveness and Safety Trial in Patients With Chronic Severe Pain
An Open-Label, Long-Term, Multi-Center, Intrathecal Ziconotide (PRIALT) Effectiveness and Safety Trial (ZEST) in Patients With Chronic Severe Pain
<http://clinicaltrials.gov/ct2/show/NCT00076544?term=zest&rank=5>
- Masters' Thesis, University of Nebraska Medical Center:
"Hypogonadism in the Chronic Pain Patient, A Review"

Professional Society Memberships:

American Academy of Pain Medicine
American Academy of Pain Management
American Pain Society
California Academy of PAs
San Diego Society of PAs
American Academy of PAs

Awards and Honors:

Golden Key National Honor Society
Alpha Eta Honor Society
Dean's List
Summa Cum Laude
Who's Who in America 60th Edition (Marquis)
Who's Who in Medicine and Healthcare 5th Edition (Marquis)